> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Expands Trevo Clot Device Indication
- URL: https://www.fdaweb.com/fda-expands-trevo-clot-device-indication/
- Published: 2018-02-15T12:00:00.000Z
- Updated: 2026-09-14T23:22:55.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5140773

FDA has approved an expanded indication for the Concentric Medical Trevo clot retrieval device to allow treatment of certain stroke patients up to 24 hours after symptom onset, expanding the use to a broader group of patients. An agency [news release](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596983.htm?ref=fdaweb.com) says the device is cleared for use as an initial therapy for acute ischemic stroke to reduce paralysis, speech difficulties, and other stroke disabilities, and only as an addition to treatment with a tissue plasminogen activator that dissolves clots. The device was previously cleared for use in patients six hours after symptom onset.

Risks associated with Trevo use include failure to retrieve the blood clot, embolization to new territories in the brain, arterial dissections and vascular perforations, and access site complications at the femoral artery entry point.